INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is startingNo dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both ...
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...